SCHEMBL7608692

SCHEMBL7608692

Clc1ccc2cc3ccc(Cl)cc3nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.52
ACHE P22303 2/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 1/20 0.50
F2 P00734 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
MAOA P21397 1/20 0.50
DRD1 P21728 1/20 0.50
PTGS1 P23219 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A4 P31645 1/20 0.50
OPRM1 P35372 1/20 0.50
DRD3 P35462 1/20 0.50
KDR P35968 1/20 0.50
HTT P42858 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17423219 0.89 MAPT (0.65) NR4A2ACHELMNAMEN1F2
SCHEMBL11057520 0.87 LMNA (0.75) NR4A2ACHELMNAMEN1F2
SCHEMBL12068392 0.82 ALDH1A1 (0.57) LMNAMEN1KMT2APDGFRBPDGFRA
SCHEMBL16500490 0.82 ESR1 (0.49) NR4A2MEN1KMT2ADYRK1AF7
SCHEMBL12068383 0.80 KDM4E (0.50) PDGFRBPDGFRARXFP1MAPTALDH1A1
SCHEMBL5157381 0.80 PIK3CG (0.58) NR4A2LMNAMEN1KMT2ADYRK1A
SCHEMBL30506415 0.79 NR4A2 (0.54) NR4A2LMNAHRH3PDGFRBPDGFRA
SCHEMBL2133059 0.79 NR4A2 (0.54) NR4A2LMNAHRH3PDGFRBPDGFRA
SCHEMBL28208080 0.79 NR4A2 (0.44) NR4A2LMNAKMT2AHRH3PDGFRB
SCHEMBL278565 0.78 NCF1 (0.56) LMNAMEN1KMT2ACYP2A6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020051751-A1 Pharmaceuticals and apparatus providing diagnosis and selective tissue necrosis MILLS RANDELL L (US) 2002-05-02 US disclosed
US-6224848-B1 Pharmaceuticals providing diagnosis and selective tissue necrosis using Mossbauer absorber atom MILLS RANDELL L (US) 2001-05-01 US disclosed
EP-0316440-B1 System and method for providing localized Mössbauer absorption in an organic medium MILLS RANDELL L (US) 1996-01-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020051751-A1 Pharmaceuticals and apparatus providing diagnosis and selective tissue necrosis TK2, POLB, ATP5PB NR4A2 1088/4885ACHE 1301/4885LMNA 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.